SCHEMBL1316009

SCHEMBL1316009

CC(NC(=O)/C(C#N)=C/c1ccc(Br)nc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.65
KMT2A Q03164 8/20 0.64
MAPT P10636 6/20 0.64
MEN1 O00255 6/20 0.64
ALDH1A1 P00352 6/20 0.64
KDM4E B2RXH2 5/20 0.64
LMNA P02545 4/20 0.64
TP53 P04637 3/20 0.64
MAPK1 P28482 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
CYP1A2 P05177 3/20 0.64
CYP3A4 P08684 3/20 0.64
CYP2C19 P33261 3/20 0.64
RGS12 O14924 2/20 0.64
GMNN O75496 2/20 0.64
CYP2C9 P11712 2/20 0.64
ALOX15 P16050 2/20 0.64
TSHR P16473 2/20 0.64
ALOX12 P18054 2/20 0.64
NFKB1 P19838 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316013 1.00 STAT3 (0.65) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1316011 1.00 STAT3 (0.65) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1316007 1.00 STAT3 (0.65) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL14403004 0.89 KMT2A (0.64) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1314737 0.81 KMT2A (0.63) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1314739 0.81 KMT2A (0.63) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1314734 0.81 KMT2A (0.63) STAT3KMT2AMAPTMEN1ALDH1A1
SCHEMBL1314736 0.81 KMT2A (0.63) STAT3KMT2AMAPTMEN1ALDH1A1
Wp 1066 SCHEMBL1315826 0.79 STAT3 (1.00) STAT3KMT2AMAPTMEN1ALDH1A1
Wp 1066 SCHEMBL1315829 0.79 STAT3 (1.00) STAT3KMT2AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130129675-A1 INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-05-23 US disclosed
US-20110275577-A1 METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, LLC (US) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275577-A1 METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS VHL, PRKDC, POLR1C STAT3 902/4885KMT2A 508/4885MAPT 4557/4885
US-20130129675-A1 INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION STAT3, STAT1, STAT5B STAT3 1/4885KMT2A 2412/4885MAPT 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.